Changes in reticulocyte hemoglobin content (Ret‑He) and serum ferritin (SF) in very preterm infants within the first 14 days after birth

Technical Summary: Changes in Reticulocyte Hemoglobin Content and Serum Ferritin in Very Preterm Infants

Problem Statement
Iron deficiency (ID) in very preterm infants (VPIs, gestational age <32 weeks) poses significant risks, including anemia and permanent neurodevelopmental impairment. Conversely, iron overload can also negatively impact development. While current guidelines (e.g., ESPGHAN) recommend initiating enteral iron supplementation at 2–3 weeks of age, there is a lack of reliable biomarkers to predict low iron status in the immediate postnatal period. Serum ferritin (SF), the standard measure of iron stores, is limited by its requirement for large blood volumes and its elevation during inflammation. Reticulocyte hemoglobin content (Ret‑He) is a promising, inflammation-resistant parameter that reflects current iron availability for erythropoiesis. The study aimed to evaluate the dynamics of Ret‑He and SF within the first 14 days of life to determine if endogenous iron stores are sufficient to support hematopoiesis without early supplementation, and to explore the utility of Ret‑He (alone or with SF) for assessing iron status.

Methodology
This was a retrospective, single-center study conducted at a tertiary maternal and child health hospital in Chongqing, China, involving 145 consecutive VPIs (GA <32 weeks) born between 2017 and 2019.

• Inclusion/Exclusion: Infants were included if they had blood samples drawn for SF and Ret‑He on postnatal day (PND) 3 ± 1 and PND 14 ± 1. Exclusion criteria included hematological diseases, congenital hemolytic disorders, coagulation disorders, maternal anemia, blood transfusions within 14 days, suspected infection (CRP >10 mg/L with clinical signs), and lack of blood collection. Crucially, no infants received enteral or parenteral iron supplementation prior to the PND 14 draw.
• Definitions: Due to the absence of a clinically validated gold standard for ID in the first two weeks of life, the authors employed an exploratory definition of low iron status as SF below the 10th percentile of the study cohort. The authors explicitly noted that this definition introduces circularity when correlating with Ret‑He and that diagnostic metrics derived from it are hypothesis-generating only.
• Data Collection: Venous blood samples were analyzed using a Sysmex XN-1000 analyzer for complete blood counts (CBC) and reticulocyte parameters (including Ret‑He), and an ARCHITECT i2000sr for SF.
• Statistical Analysis: Comparisons between PND 3 and PND 14 utilized paired t-tests or Wilcoxon signed-rank tests. Receiver Operating Characteristic (ROC) analysis was performed to evaluate the association of Ret‑He and other indices with the exploratory low-iron definition. Subgroup analyses were conducted by gestational age (<30 vs. ≥30 weeks) and delayed cord clamping (DCC) status, though these were descriptive due to limited sample sizes.

Key Results

• Demographics: The cohort had a mean gestational age of 30.1 weeks and a mean birth weight of 1431.2 g. Delayed cord clamping (DCC) was performed in 49.7% of infants.
• Serum Ferritin (SF): SF increased significantly from a median of 178.50 µg/L on PND 3 to 220.00 µg/L on PND 14 (P < 0.01). This rise occurred despite the absence of exogenous iron.
• Reticulocyte Hemoglobin Content (Ret‑He): Ret‑He showed no significant difference between PND 3 (median 28.80 pg) and PND 14 (median 28.70 pg) (P = 0.37). The regression slope for Ret‑He was negligible (−0.01 pg/day).
• Other Hematological Parameters: Hemoglobin (Hb), Mean Corpuscular Volume (MCV), and Mean Corpuscular Hemoglobin (MCH) decreased significantly from PND 3 to PND 14 (P < 0.0001), consistent with physiological changes and phlebotomy losses. Mean Corpuscular Hemoglobin Concentration (MCHC) increased slightly but significantly.
• Diagnostic Performance: In the exploratory analysis using the 10th percentile SF cutoff, Ret‑He demonstrated limited ability to discriminate low from normal iron status, with Area Under the Curve (AUC) values of 0.57 on PND 3 and 0.51 on PND 14. A Ret‑He cutoff of 26.25 pg on PND 3 yielded 100% sensitivity but only 30.6% specificity; on PND 14, a cutoff of 24.80 pg yielded 100% sensitivity and 16.4% specificity. The authors emphasized that these high sensitivity values are mathematical consequences of deriving cutoffs from the same dataset and should not be interpreted as clinical validation.
• Subgroup Analysis: The pattern of rising SF and stable Ret‑He appeared consistent across gestational age subgroups (<30 weeks vs. ≥30 weeks) and DCC status, though formal statistical comparisons were not performed due to the exploratory nature of the study.

Significance and Claims
The authors conclude that within the first 14 days after birth, endogenous iron stores in very preterm infants are generally sufficient to support hematopoiesis. The significant increase in SF, likely driven by the release of iron from transient physiological hemolysis, suggests that routine iron supplementation before day 14 may not be necessary for all VPIs.

The study highlights that Ret‑He remains stable during this period, indicating that iron-restricted erythropoiesis is not prevalent in the first two weeks of life for this population. However, the authors are modest regarding the diagnostic utility of Ret‑He in this specific window. They assert that the low AUC values reflect the unsuitability of SF as a standalone gold standard during a period of physiological hemolysis and inflammation, rather than a failure of Ret‑He itself.

Limitations and Future Directions
The paper explicitly acknowledges several limitations: the circularity of the exploratory low-iron definition, the potential confounding effect of subclinical inflammation on SF, the incomplete documentation of DCC duration, the retrospective single-center design, and the lack of other iron biomarkers (e.g., soluble transferrin receptor, zinc protoporphyrin-to-heme ratio, hepcidin).

Consequently, the authors do not propose immediate changes to clinical protocols based solely on these findings. Instead, they call for prospective, multi-marker studies to confirm the stability of Ret‑He and SF dynamics and to determine the optimal timing for individualized iron supplementation in very preterm infants.